



Tremfya in Egypt

The EDA named-patient coordination pathway — indicative 2026

IMMUNOLOGY · IL-23 P19

The clinical situation

Tremfya (guselkumab) is an FDA-approved fully human monoclonal antibody to the p19 subunit of IL-23 indicated for moderate-to-severe plaque psoriasis and psoriatic arthritis. Manufactured by Janssen. Standard dosing is 100 mg SC at weeks 0 and 4 then every 8 weeks; refrigerated storage 2-8°C, patient- or provider-administered auto-injector or pre-filled syringe.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating dermatologist or rheumatologist documents PASI/BSA or PsA activity, TB/HBV/HCV screening, and prior biologic history.
- 2 Treating centre confirmed.** An Egyptian tertiary dermatology or rheumatology centre in Cairo, Alexandria, or Giza accepts the case.
- 3 EDA named-patient application.** Clinical rationale, patient reference, product details, and cold-chain plan are filed under EDA personal-import; customs release coordination.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; temperature-monitored 2-8°C shipment.
- 5 Arrival & administration.** Patient self-administers SC at home after nurse training; response reassessed at 16 weeks.

Indicative economics

Reference US cash-pay range: USD 12,000–14,000 per 8-week dose. EDA documentation, cold-chain logistics, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete EDA application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and EDA review. **Logistics.** Temperature-monitored cold-chain shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating specialist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Tremfya × Egypt first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/tremfya-egypt.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team